Tiedemann Advisors’s Kyntra Bio KYNB Stock Holding History

Tiedemann Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-605	Closed	-$560K	–	309
2019 Q3	$560K	Buy	605 +4	+0.7%	+$4.39K	0.03%	213
2019 Q2	$679K	Hold	601	–	–	0.03%	180
2019 Q1	$817K	Hold	601	–	–	0.04%	240
2018 Q4	$695K	Hold	601	–	–	0.04%	249
2018 Q3	$913K	Hold	601	–	–	0.05%	179
2018 Q2	$941K	Hold	601	–	–	0.06%	168
2018 Q1	$694K	Hold	601	–	–	0.05%	173
2017 Q4	$712K	Hold	601	–	–	0.05%	136
2017 Q3	$808K	Buy	601 +251	+72%	+$264K	0.07%	169
2017 Q2	$1.9M	Sell	350 -831	-70%	-$579K	0.14%	131
2017 Q1	$2.04M	Buy	1,181 +93	+9%	+$56.6K	0.17%	115
2016 Q4	$1.47M	Sell	1,088 -659	-38%	-$329K	0.15%	113
2016 Q3	$734K	Buy	+1,747	New	+$823K	0.15%	77

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Tiedemann Advisors's KYNB Position: Q4 2019 in Review

Tiedemann Advisors sold out of Kyntra Bio (KYNB) in Q4 2019, closing a stake of 605 shares — an estimated $560K sold.

Tiedemann Advisors first reported a position in KYNB in Q3 2016 and held it in 13 quarters. The position peaked at $2.04M in Q1 2017. 213 funds tracked by Wall St. Rank hold KYNB as of Q4 2019.

Tiedemann Advisors reported no remaining Kyntra Bio position as of Q4 2019 after selling out during the quarter.
Tiedemann Advisors sold 605 Kyntra Bio shares in Q4 2019, an estimated $560K.
Tiedemann Advisors first reported a position in Kyntra Bio in Q3 2016 and held it in 13 quarters.
Tiedemann Advisors's Kyntra Bio position peaked at $2.04M in Q1 2017.
213 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2019.

Based on Tiedemann Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.